CD8A and hepatocellular carcinoma: To determine whether circulating TAA-specific CD8+ T-cell responses are specific for cancer patients, in this case for HCC, we next compared their detection rates and frequencies in HCC patients with the detectability in healthy donors (HD; n = 28; Supplementary Table 2) and in patients with liver cirrhosis (n = 29; Supplementary Table 3).